Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04642963
Other study ID # SMART-VT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 11, 2020
Est. completion date January 10, 2023

Study information

Verified date March 2023
Source Maria Sklodowska-Curie National Research Institute of Oncology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective single-arm study investigating the safety of non-invasive cardiac radiosurgery for the treatment of ventricular tachycardia (VT).


Description:

The standard of care for the treatment of Ventricular Tachycardia (VT) comprises of pharmacotherapy, ICD implantation and electrophysiology-guided catheter ablation. The treatment, however, is associated with a relatively high risk of VT recurrence. Given the limited therapeutic options and significant impact on patients quality of life, non-invasive cardiac radiosurgery has been recently gaining popularity in scientific literature as a viable alternative to salvage catheter ablations. Considering the scarcity of data from prospective trials and concern about the safety of the treatment method, this trial seeks to determine whether Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia (SMART-VT) meets the expected safety requirements for clinical use.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date January 10, 2023
Est. primary completion date January 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with structural heart disease and implantable cardioverter defibrillator (ICD) - Clinically significant arrhythmia with at least 3 VT episodes per month despite adequate pharmacological treatment. - At least one episode of monomorphic VT registered in electrophysiological examination. - Recurrent VT despite at least one prior catheter ablation and adequate pharmacotherapy OR contraindications to catheter ablation and/or pharmacotherapy (i.e., patient with medically contraindicated catheter ablation is obliged to undergo only pharmacotherapy prior to study enrollment). - Patient must be able to understand and be willing to sign a written informed consent document. Exclusion Criteria: - Heart failure requiring inotropic treatment or mechanical assistance - Arrhythmia due to cardiac channelopathy - Reversible source of arrhythmia - NYHA (New York Heart Association) stage IV hearth failure - Hearth infarction or cardiac surgery in last 3 months - Life expectancy <6 months - Polymorphic VT - Pregnancy - Prior radiotherapy to the thoracic region (relative contraindication) - Failure to induce VT during electrophysiological examination

Study Design


Intervention

Radiation:
Cardiac Radiosurgery
Non-invasive delivery of ablative radiotherapy dose to the arrhythmia substrate.

Locations

Country Name City State
Poland Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Gliwice branch Gliwice Slaskie
Poland Upper Silesian Medical Center Professor Leszek Giec of the Medical University of Silesia in Katowice Katowice

Sponsors (1)

Lead Sponsor Collaborator
Maria Sklodowska-Curie National Research Institute of Oncology

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute toxicity evaluated using CTCAE v5.0 scale The study aims to demonstrate the safety of the treatment method defined as 3-month observation without Grade III or higher adverse events in at least 6 out of 7 patients (1st stage), and in total in at least 9 out of 11 patients (2nd stage) with an interim safety analysis after obtaining data on primary outcome in first 7 patients. 3 months
Secondary Efficacy of the treatment Reduction of VT burden, ICD shocks and improvement in life quality as described by SF-36 (The Short Form Health Survey) v2 questionnaire. f eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. 24 months
Secondary Biochemical markers of cardiac injury Intensity and dynamics of changes in cardiac-related biochemical indices after treatment, like troponin, cardiac creatine kinase (MB-CK) concentration and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) to assess the early cardiac muscle damage and changes in severity of congestive heart failure. 24 months
Secondary Late toxicity and mortality Assessment of late toxicity including occurrence of cardiac-related hospitalizations and death. 24 months
Secondary Anti-arrhythmic drugs uptake Changes in the anti-arrhythmic medications over time after treatment. 24 months
Secondary Cardiac injury Assessment of the post-treatment cardiac injury including left ventricular ejection fraction, echocardiography and morphological changes in imaging studies. 24 months
Secondary Target volume delineation Correlation of electrophysiological mapping with the results of additional cardiac imaging methods (MR, PET) - only in applicable patients (optional diagnostic methods) 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT03453645 - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed NCT05791032 - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study N/A
Completed NCT05970120 - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter N/A
Completed NCT04011631 - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System. N/A
Recruiting NCT03536052 - Ablation at Virtual-hEart pRedicted Targets for VT N/A
Not yet recruiting NCT06063811 - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation NCT02962076 - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia Early Phase 1
Not yet recruiting NCT02784912 - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation N/A
Completed NCT01791543 - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia N/A
Terminated NCT02891863 - Low Energy Therapy to Convert Ventricular Tachycardias Phase 0
Terminated NCT01546207 - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia N/A
Completed NCT01294267 - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation N/A
Terminated NCT00383799 - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia Phase 4
Completed NCT04884100 - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening N/A
Recruiting NCT05377216 - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation Early Phase 1
Not yet recruiting NCT04990089 - VIVO European Observational Registry
Completed NCT04065893 - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting NCT03631303 - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting NCT03611465 - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts N/A
Suspended NCT05478213 - Ventricular Tachycardia Mechanisms N/A